Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
14,617
Total Claims
$1.5M
Drug Cost
617
Beneficiaries
$2,448
Cost/Patient
Risk Score Breakdown 3/100
Score components are additive. Read full methodology
Peer Comparison vs. 106,889 Family Practice providers
+129%
Cost per patient vs peers
$2,448 vs $1,068 avg
+39%
Brand preference vs peers
12.5% vs 9.0% avg
Brand vs Generic
Brand: 1,784 claims · $1.1M
Generic: 12,465 claims · $412K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Sitagliptin Phosphate | 159 | $194K |
| Icosapent Ethyl | 395 | $176K |
| Icosapent Ethyl | 318 | $104K |
| Empagliflozin | 88 | $99K |
| Rivaroxaban | 77 | $84K |
| Sitagliptin Phos/Metformin Hcl | 64 | $74K |
| Apixaban | 67 | $61K |
| Dapagliflozin Propanediol | 54 | $58K |
| Diclofenac Epolamine | 69 | $47K |
| Denosumab | 25 | $43K |
| Lipase/Protease/Amylase | 51 | $38K |
| Raloxifene Hcl | 339 | $35K |
| Varicella-Zoster Ge/As01b/Pf | 149 | $30K |
| Linagliptin | 23 | $27K |
| Atorvastatin Calcium | 1,338 | $17K |
Prescribing Profile
Patient Profile
73
Avg Age
53%
Female
1.02
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data